These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 16536115

  • 1. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P.
    J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
    [Abstract] [Full Text] [Related]

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
    Encephale; 2005 Sep; 31(2):235-46. PubMed ID: 15959450
    [Abstract] [Full Text] [Related]

  • 3. Did CATIE influence antipsychotic use?
    Citrome L, Jaffe A, Martello D, Allingham B, Levine J.
    Psychiatr Serv; 2008 May; 59(5):476. PubMed ID: 18451000
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [Abstract] [Full Text] [Related]

  • 5. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y, Kim E, You M, Pikalov A, Tran QV.
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [Abstract] [Full Text] [Related]

  • 6. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost.
    Mortimer A, Williams P, Meddis D.
    J Int Med Res; 2003 Jun; 31(3):188-96. PubMed ID: 12870371
    [Abstract] [Full Text] [Related]

  • 7. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
    Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.
    BMC Psychiatry; 2008 Apr 04; 8():19. PubMed ID: 18394168
    [Abstract] [Full Text] [Related]

  • 8. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.
    J Clin Psychiatry; 2008 Dec 04; 69(12):1901-15. PubMed ID: 19012820
    [Abstract] [Full Text] [Related]

  • 9. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
    San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, Dueñas R, Alvarez E.
    Psychiatry Res; 2012 Dec 30; 200(2-3):693-701. PubMed ID: 22954905
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
    Park T, Kuntz KM.
    Value Health; 2014 Jun 30; 17(4):310-9. PubMed ID: 24968989
    [Abstract] [Full Text] [Related]

  • 11. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M, Okamoto MP.
    J Eval Clin Pract; 2007 Jun 30; 13(3):453-60. PubMed ID: 17518814
    [Abstract] [Full Text] [Related]

  • 12. Ziprasidone versus other atypical antipsychotics for schizophrenia.
    Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S.
    Cochrane Database Syst Rev; 2009 Oct 07; (4):CD006627. PubMed ID: 19821380
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
    Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, CATIE Investigators.
    Am J Psychiatry; 2006 Apr 07; 163(4):611-22. PubMed ID: 16585435
    [Abstract] [Full Text] [Related]

  • 14. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
    Lubinga SJ, Mutamba BB, Nganizi A, Babigumira JB.
    Appl Health Econ Health Policy; 2015 Oct 07; 13(5):493-506. PubMed ID: 25958192
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.
    Pharmacoeconomics; 2005 Oct 07; 23 Suppl 1():75-89. PubMed ID: 16416763
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I, IC-SOHO Study Group.
    J Clin Psychiatry; 2004 Mar 07; 65(3):312-21. PubMed ID: 15096069
    [Abstract] [Full Text] [Related]

  • 17. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.
    Value Health; 2004 Mar 07; 7(1):22-35. PubMed ID: 14720128
    [Abstract] [Full Text] [Related]

  • 18. What CATIE found: results from the schizophrenia trial.
    Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA.
    Psychiatr Serv; 2008 May 07; 59(5):500-6. PubMed ID: 18451005
    [Abstract] [Full Text] [Related]

  • 19. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.
    Pharmacoeconomics; 2005 May 07; 23 Suppl 1():35-47. PubMed ID: 16416760
    [Abstract] [Full Text] [Related]

  • 20. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.
    Gianfrancesco F, Pesa J, Wang RH.
    J Manag Care Pharm; 2005 Apr 07; 11(3):220-30. PubMed ID: 15804206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.